| ALECTINIB |
Alecensa® |
ROCHE PRODUCTS PTY LTD |
Non-small cell lung cancer (NSCLC) |
May 2025 |
|
| BIMEKIZUMAB |
Bimzelx® |
UCB AUSTRALIA PROPRIETARY LIMITED |
Hidradenitis suppurativa (HS) |
May 2025 |
|
| DOSTARLIMAB |
Jemperli® |
GLAXOSMITHKLINE AUSTRALIA PTY LTD |
Endometrial cancer |
May 2025 |
|
| DURVALUMAB TREMELIMUMAB |
|
ASTRAZENECA PTY LTD |
Barcelona clinic liver cancer (BCLC) Hepatocellular carcinoma (HCC) |
May 2025 |
|
| EMPAGLIFLOZIN |
Jardiance® |
BOEHRINGER INGELHEIM PTY LTD |
Chronic kidney disease (CKD) |
May 2025 |
|
| ETONOGESTREL WITH ETHINYLESTRADIOL |
NuvaRing® |
ORGANON PHARMA PTY LTD |
Contraception |
May 2025 |
|
| FEDRATINIB |
Inrebic® |
BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD |
Myelofibrosis (MF) |
May 2025 |
|
| GUSELKUMAB |
Tremfya® |
JANSSEN-CILAG PTY LTD |
Chronic plaque psoriasis (CPP) |
May 2025 |
|
| NIRSEVIMAB |
Beyfortus® |
SANOFI-AVENTIS AUSTRALIA PTY LTD |
Prevention of lower respiratory tract disease caused by respiratory syncytial virus
(RSV) |
May 2025 |
|
| OMALIZUMAB |
Xolair® |
NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED |
Chronic rhinosinusitis with nasal polyps (CRSwNP) |
May 2025 |
|
| OSIMERTINIB |
Tagrisso® |
ASTRAZENECA PTY LTD |
Non-small cell lung cancer (NSCLC) |
May 2025 |
|
| PEGCETACOPLAN |
Empaveli® |
SWEDISH ORPHAN BIOVITRUM PTY LTD |
Paroxysmal nocturnal haemoglobinuria (PNH) |
May 2025 |
|
| PIOGLITAZONE |
Actos® |
CELLTRION HEALTHCARE AUSTRALIA PTY LTD |
Type 2 diabetes mellitus |
May 2025 |
|
| RANIBIZUMAB |
Lucentis® |
NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED |
Proliferative diabetic retinopathy (PDR) |
May 2025 |
|
| RAXTOZINAMERAN |
Comirnaty® |
PFIZER AUSTRALIA PTY LTD |
Prevention of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 |
May 2025 |
|
| REPOTRECTINIB |
Augtyro™ |
BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD |
Non-small cell lung cancer (NSCLC) |
May 2025 |
|
| TEPROTUMUMAB |
Tepezza® |
AMGEN AUSTRALIA PTY LTD |
Thyroid Eye Disease (TED) |
May 2025 |
|
| TRASTUZUMAB DERUXTECAN |
Enhertu® |
ASTRAZENECA PTY LTD |
Gastric or gastroesophageal junction (G/GOJ) cancer |
May 2025 |
|
| UBLITUXIMAB |
Briumvi® |
KIRCHMANN ENTERPRISES PTY LTD |
Relapsing-remitting multiple sclerosis (RRMS) |
May 2025 |
|